Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Fujifilm's new CAD EYE™ function for real time colon polyp Detection and Characterisation utilising AI technology is now commercially available in Europe


News provided by

FUJIFILM Europe

18 Sep, 2020, 09:23 GMT

Share this article

Share toX

Share this article

Share toX

DÜSSELDORF, Germany, Sept. 18, 2020 /PRNewswire/ -- FUJIFILM Europe GmbH announced today that CAD EYE™ is now commercially available in Europe. CAD EYE™ is a new software with two functions for colon polyp detection and characterisation utilising Artificial Intelligence (AI) based on deep learning. The official presentation will take place during an ESGE Connect 2020 Satellite Symposium, on Monday 21st September 2020 at 5:00 pm.

Continue Reading
This image opens in the lightbox
Expansion Unit EX-1 (PRNewsfoto/FUJIFILM Europe)
This image opens in the lightbox
CAD EYE - Fujifilm Artificial Intelligence meets Endoscopy (PRNewsfoto/FUJIFILM Europe)

The characterisation function together with the polyp detection function is available with software EW10-EC02 and the compatible expansion unit EX-1 in combination with Fujifilm's ELUXEO 7000 system and the 700 series colonoscopes.

CAD EYE was originally developed to support real time detection of colonic polyps utilising AI technology. When a suspicious polyp is detected within the endoscopic image, a Detection Box indicates the area where the suspicious polyp has been detected accompanied by a sound signal. The CAD EYE Characterisation module will assist clinicians by generating a suggested histological prediction by displaying whether the suspicious polyp in the image  is hyperplastic or neoplastic.

CAD EYE functions while the moving endoscopy image is being observed and does not require complicated techniques or operations such as magnification and image capturing.

Prior to CAD EYE, Fujifilm has developed two different types of image enhancement technologies called LCI (Linked Color Imaging) and BLI (Blue Light Imaging) for supporting detection and characterisation respectively due to their characteristics of light wavelength used (2*). Fujifilm has applied this idea to the development of CAD EYE, and CAD EYE's functionalities are automatically activated depending on the current observation mode.

CAD EYE Detection is activated when the clinicians are observing in White Light Mode or LCI Mode, and it automatically switches to CAD EYE Characterisation when the observation mode is changed to BLI Mode. CAD EYE can be activated or deactivated simply with just one click of the scope switch, which is also considered important when the functions are no longer necessary such as during therapeutic procedures.

The Graphical User Interface (GUI) was designed to minimise the endoscopists' eye movements during a procedure, displaying the characterisation result and the Visual Assist Circle around the circumference of the endoscopy image. The Position Map is placed directly next to the side of the clinical image to show which area of the video image CAD EYE is focusing on.

"Increasing the number of endoscopists who can properly detect and characterise colon polyps is one of the critical issues in the gastroenterology field," says Prof. Helmut Neumann, Professor of Medicine and Director Interdisciplinary Endoscopy Center of University Medical Center Mainz. "With the combination of CAD EYE Detection and Characterisation, the learning curve of colonoscopy examinations can be largely improved. With the assistance of CAD EYE Detection, we can possibly see an increase in the Polyp Detection Rate (PDR), and even those who are not endoscopy experts may be brought considerably closer to this level. CAD EYE Characterisation has the potential to decrease the cost of histopathology by reducing unnecessary biopsies taken during endoscopy procedures. It is helpful that CAD EYE is available with any 700 series colonoscopes which are already in the market, and it does not require any additional operation to be activated such as magnification. Endoscopists can simply use the scope just as normal, instantly providing us with this powerful supporting tool."

As for the detailed information regarding the instructions for use, warnings, and precautions, please refer to the operation manual. For further inquiries, please contact Fujifilm's subsidiaries or authorised distributors in each country or region.

To discover the benefits of CAD EYE during colorectal endoscopic practise, connect with us at ESGE Connect Satellite Symposium: Monday, 21st September 2020, 5.00 pm for a free webinar.

The webinar consists of pre-recorded lectures with live Q&A, with the participation of Prof. Pradeep Bhandari, University of Portsmouth, Solent centre for Digestive Diseases, Queen Alexandra Hospital,Portsmouth, UK; Prof. Dr.Emmanuel Coron Digestive Diseases Institute University Hospital of Nantes, France; Dr. Emanuele Rondonotti Gastroenterology Unit, Hospital Valduce, Como, Italy

Background:

Colorectal cancer is the third most common cancer after lung cancer and breast cancer in terms of the number of cases, and the second most common cause of cancer death after lung cancer (3*). And in order to reduce the incidence of cancer, colonoscopy is widely considered the gold standard for detection of colonic neoplasia. Also, it is widely believed that accurate endoscopic diagnosis of colonic polyps could decrease the number of unnecessary polypectomies, which can lead to the reduction of medical expenses. However, there is a gap in diagnostic capability of colon polyps between endoscopy specialists and non-specialists, and filling this gap has been one of the major issues in colonoscopy. (4*, 5*)

Fujifilm is working to develop a unique collection of image processing technologies and continues to develop the practical application of AI technology, and will continue to develop and supply a wide range of products and services that meet the needs of frontline medicine in various fields, contributing to streamlining clinical work, enhancing the quality of medical care and maintaining and strengthening people's health.

(1*) Fujifilm's brand name of function to assist computer-aided-diagnosis (CAD) in endoscopy utilising AI technologies. Fujifilm has applied for trademark protection of CAD EYE.

(2*) BLI Portal

https://www.bli.eu/about-multi-light/about-lci/

https://www.bli.eu/about-multi-light/about-bli/

(3*) WHO database

https://www.who.int/news-room/fact-sheets/detail/cancer

(4*) Ladabaum U, Fioritto A, Mitani A, et al. Real-time optical biopsy of colon polyps with narrow band imaging in community practice does not yet meet key thresholds for clinical decisions. Gastroenterology 2013;144:81–91.

(5*) Rees CJ, Rajasekhar PT, Wilson A, et al. Narrow band imaging optical diagnosis of small colorectal polyps in routine clinical practice: the Detect Inspect Characterise Resect and Discard 2 (DISCARD 2) study. Gut 2017;66:887–95.

About FUJIFILM Europe GmbH

FUJIFILM Europe GmbH (Düsseldorf, Germany) acts as strategic headquarter for the region and supports its group companies in Europe by formulating marketing and corporate strategies. Fujifilm entities operate in over 50 group companies and branches in Europe and employ around 4,500 people engaged in R&D, manufacturing, sales, and service. Throughout Europe they serve a range of industries including medical technology, graphic systems, electronic materials, chemicals, optical devices, recording media, and photography. Over the last decade, the company has more intensively focused on healthcare, and now looks back on over 80 years of experience in medical imaging. Today, Fujifilm provides the entire spectrum of patient care, ranging from prevention to diagnostics and therapy solutions. Research and development in medicine, bio-pharmaceuticals, as well as regenerative medicine are part of Fujifilm's unique portfolio.

For more information, please visit: www.fujifilm.eu 

Photo - https://mma.prnewswire.com/media/1274889/FUJIFILM_Expansion_Unit_EX_1.jpg  
Photo - https://mma.prnewswire.com/media/1274890/Fujifilm_CAD_EYE.jpg

Related Links

https://www.fujifilm.eu/

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.